News | May 14, 2012

Subcutaneous Implantable Defibrillator Shows Continued Positive Results

New data from the international EFFORTLESS registry shows the S-ICD system as a viable option for most ICD patients


May 14, 2012 – Initial results from the international Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS (EFFORTLESS) subcutaneous implantable defibrillator (S-ICD) registry shows the S-ICD system is performing appropriately in real-world circumstances and continues to show positive results in patients. This data was presented for the first time at the Heart Rhythm Society (HRS) 2012 annual scientific sessions in Boston.

Data analyzed from the largest study of real world experience using the SICD System to-date, demonstrated a conversion rate of more than 98 percent for induced and ambulatory ventricular tachycardia or fibrillation (VT/VF), consistent with transvenous ICD systems.

The purpose of an ICD is to convert all episodes of VT/VF through a defibrillation shock to the heart.  The S-ICD system is a new generation of the ICD that does not require intravascular leads.  Instead, the S-ICD system electrode is inserted under the skin and outside of the ribcage.  The S-ICD System is an alternative for most patients requiring protection from sudden cardiac arrest (SCA).  However, the S-ICD system is not intended for those patients having bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring ventricular tachycardia that is reliably terminated with anti-tachycardia pacing.

The EFFORTLESS registry was designed to evaluate the long-term performance of the S-ICD system, including patient quality of life and long-term resource utilization.  The registry is an observational, non-randomized, standard of care evaluation collecting data at international investigational centers where the S-ICD System is approved for use and distribution. 

Data from 230 patients that received an S-ICD system at clinical centers in nine countries, including the United Kingdom, Netherlands, Czech Republic, Slovakia, Denmark, Italy, Germany, Portugal and New Zealand, were reviewed and showed:

• 64 percent were for primary prevention (of which 49 percent were ischemic).

• Ischemic indications accounted for 38 percent of all patients implanted

• Channelopathies (including Brugada syndrome; Long-QT syndrome and CPVT) accounted for 13 percent of all patients implanted

• 28 patients received ambulatory shock therapy (13 percent; n=72 episodes):

     - 48 spontaneous VT/VF episodes were all appropriately converted

     - Annual inappropriate shock rate was seven percent

• Induced shock conversion efficacy within one procedure was 98.5 percent with an average time to therapy for the first shock of 16±4 seconds.

• No patient received therapy for any SVTs (including atrial fibrillation) within a programmed conditional shock zone.

“This data shows us that the S-ICD system is proving to be safe and effective and possibly even a slightly better option than a regular ICD for certain patients,” said Pier D. Lambiase, M.D., Ph.D., FRCP, lead author and senior lecturer and honorary consultant cardiologist at Heart Hospital, University College of London.  “Our goal is to provide patients with heart devices that are less invasive, yet perform the same or better than other options.  Real-world data is critical for us to understand therapy outcomes and so far we are very impressed with the performance of the S-ICD system in a wide range of patients.”

On April 26, 2012, the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel recommended approval of Cameron Health’s S-ICD system.  This recommendation was a result of a 7-1 panel vote in favor of sufficient data demonstrating the efficacy and safety of the S-ICD System for the treatment of SCA.

The S-ICD system was introduced in Europe in 2009 and results from the first 98 patients were presented at Heart Rhythm 2011.

For more information: www.HRSonline.org

 

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now